Gastroesophageal adenocarcinoma (GEC) remains a challenging problem in oncology. GEC remains the fourth most common malignancy and the second most common cause of death worldwide. Gastroesophageal junction (GEJ) adenocarcinomas have an estimated 350% increase in incidence in the US in the last two to three decades for unclear reasons. GEC is a molecularly heterogeneous disease both between patients (inter-patient) and within an individual patient (intra-patient). Intra-patient heterogenety manifests through space (primary tumor to metastatic lymph nodes to distant metastases, and even across different metastases) and time (natural selection of genomic aberrations conferring growth/metastatic advantage, as well as evolution of treatment resistant clones over time). Inter- and intra-patient tumor heterogeneity has likely contributed to negative results in a number of recent clinical trials testing novel molecularly targeted therapeutics using a 'one-size-fits-all'approach. Tumor heterogeneity poses a significant hurdle to achieving personalized treatment, particularly when using standard/accepted clinical trial designs. This proposal seeks to address inter-patient tumor heterogeneity by assigning treatment based on predefined predictive molecular 'oncogenic driver'categories, namely, HER2, MET, FGFR2, EGFR/HER3, and KRAS/PI3K-like. These are the most frequently observed molecular categories within GEC cell lines and tumor tissues. A comprehensive molecular profiling of the tumor at diagnosis will be done on the primary tumor and a metastatic disease site (liver, lung, or peritoneum) at enrollment, and all patients will be assigned to one of five specific treatments based on their metastatic tumor molecular profile as assessed via a novel treatment assignment algorithm. [This treatment algorithm is a compromise between the vast number of potential treatment groups and the feasibility of conducting such a trial and acquiring the many investigational agents necessary.] Metastatic disease will be uniformly used to profile the tumor in order to address intra-patient tumor heterogeneity through space, which can account for an approximate 10-15% discordant rate, resulting in subset misclassification. Additionally, patients will have planned serial biopsies at each progression point to determine molecular evolution over time and treatment. The correlative science incorporated into this study design will greatly improve our understanding of the disease with respect to inter-patient and intra-patient heterogeneity, and also will help to shed light on how to best address these hurdles in order to truly treat with molecular therapies for specific molecular targets, despite each molecular category occurring relatively infrequently. The feasibility and safety endpoints of this novel [pilot trial] are accompanied by a preliminary efficacy endpoint of overall survival [for the HER2+ and MET+ subgroups (N=68)], as compared to recent historical controls of approximately 12 months as seen in these GEC patients. [Secondary endpoints will include analysis of overall survival and other clinical endpoints amongst all five subgroups, anticipated to be approximately 104 patients]. This clinical trial design is innovative with its biostastistical approach and in its atempt to improve our understanding of the molecular biology of the disease, address inter- and intra-patient tissue heterogeneity within the disease, and to achieve our ultimate goal of molecularly personalized cancer care in order to significantly improve clinical outcomes.
Gastroesophageal adenocarcinoma (GEC) remains the fourth most common malignancy worldwide and the second most common cause of death worldwide, with some types having an estimated 350% increase in incidence in the United States in the last two to three decades for unclear reasons. Five molecular subsets of the disease have been defined, and the key oncoprotein of each subset has a number of pharmaceutical agents developed to specifically inhibit its function. Evaluating each of these subsets independently has proven difficult, given the small proportion of each within the total GEC patient population, and the consequent difficulties with slow trial accrual;therefore, a novel clinical trial design which assigns each patient screened to one of the five arms with a paired assigned treatment, within this one single pilot trial, is proposed. Ultimately, if this strategy proves feasible and early efficacy endpoints are promising, subsequent randomized placebo controlled trials are planned, which may prove to be practice changing for the treatment of cancer patients.
|Joshi, Smita S; Maron, Steven B; Catenacci, Daniel V (2017) Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma. Future Oncol :|
|Maron, Steven B; Catenacci, Daniel V T (2017) Update on Gastroesophageal Adenocarcinoma Targeted Therapies. Hematol Oncol Clin North Am 31:511-527|
|Maron, Steven B; Catenacci, Daniel V T (2017) Novel Targeted Therapies for Esophagogastric Cancer. Surg Oncol Clin N Am 26:293-312|
|Catenacci, Daniel V T; Ang, Agnes; Liao, Wei-Li et al. (2017) MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma. Cancer 123:1061-1070|
|An, E; Ock, C-Y; Kim, T-Y et al. (2017) Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment. Ann Oncol 28:110-115|
|Catenacci, Daniel V T; Tebbutt, Niall C; Davidenko, Irina et al. (2017) Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18:1467-1482|
|Guo, Wentian; Ji, Yuan; Catenacci, Daniel V T (2017) A subgroup cluster-based Bayesian adaptive design for precision medicine. Biometrics 73:367-377|
|Sellappan, Shankar; Blackler, Adele; Liao, Wei-Li et al. (2016) Therapeutically Induced Changes in HER2, HER3, and EGFR Protein Expression for Treatment Guidance. J Natl Compr Canc Netw 14:503-7|
|Catenacci, Daniel V T; Liao, Wei-Li; Zhao, Lei et al. (2016) Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH. Gastric Cancer 19:1066-79|
|Catenacci, Daniel V T; Chapman, Christopher G; Xu, Peng et al. (2015) Acquisition of Portal Venous Circulating Tumor Cells From Patients With Pancreaticobiliary Cancers by Endoscopic Ultrasound. Gastroenterology 149:1794-1803.e4|
Showing the most recent 10 out of 16 publications